John Lauriello

Summary

Affiliation: University of New Mexico
Country: USA

Publications

  1. ncbi request reprint Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia
    John Lauriello
    Department of Psychiatry, University of New Mexico, 2400 Tucker Avenue NE, Albuquerque, NM 87131, USA
    Psychiatr Clin North Am 26:191-211. 2003
  2. ncbi request reprint Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia
    John Lauriello
    Department of Psychiatry MSC095030, 1 University of New Mexico Health Sciences Center, Albuquerque, NM 87131 001, USA
    Schizophr Res 72:249-58. 2005
  3. ncbi request reprint An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia
    John Lauriello
    Department of Psychiatry, University of New Mexico, Albuquerque, NM 87131 001, USA
    J Clin Psychiatry 69:790-9. 2008
  4. ncbi request reprint Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia
    Juan R Bustillo
    Department of Psychiatry, University of New Mexico, Albuquerque, NM 87131 0001, USA
    Neuropsychopharmacology 33:2456-66. 2008
  5. pmc The MCIC collection: a shared repository of multi-modal, multi-site brain image data from a clinical investigation of schizophrenia
    Randy L Gollub
    Department of Psychiatry, Massachusetts General Hospital, Building 120, Suite 101D, Charlestown, MA 02129 2000, USA
    Neuroinformatics 11:367-88. 2013
  6. pmc Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla
    Juan R Bustillo
    Department of Psychiatry, University of New Mexico, Albuquerque, New Mexico, USA
    Biol Psychiatry 69:19-27. 2011
  7. pmc Dysregulation of working memory and default-mode networks in schizophrenia using independent component analysis, an fBIRN and MCIC study
    Dae Il Kim
    The MIND Research Network, Albuquerque, New Mexico 87131, USA
    Hum Brain Mapp 30:3795-811. 2009
  8. ncbi request reprint Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure
    Juan R Bustillo
    Department of Psychiatry, Research Division, University of New Mexico, 2400 Tucker NE, Albuquerque, NM 87131, USA
    Schizophr Res 58:313-21. 2002
  9. ncbi request reprint Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels
    Juan Bustillo
    Department of Psychiatry, University of New Mexico Health Sciences Center, Albuquerque, NM 87131 0001, USA
    Neuropsychopharmacology 31:751-6. 2006
  10. ncbi request reprint Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study
    Laura M Rowland
    Department of Psychiatry, MIND Imaging Center, University of New Mexico, USA
    Am J Psychiatry 162:394-6. 2005

Research Grants

Detail Information

Publications24

  1. ncbi request reprint Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia
    John Lauriello
    Department of Psychiatry, University of New Mexico, 2400 Tucker Avenue NE, Albuquerque, NM 87131, USA
    Psychiatr Clin North Am 26:191-211. 2003
    ....
  2. ncbi request reprint Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia
    John Lauriello
    Department of Psychiatry MSC095030, 1 University of New Mexico Health Sciences Center, Albuquerque, NM 87131 001, USA
    Schizophr Res 72:249-58. 2005
    ..5%; P < 0.01). Long-acting risperidone was well tolerated. Long-acting risperidone initiated during inpatient treatment may be an important strategy in improving long-term outcomes among patients with schizophrenia...
  3. ncbi request reprint An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia
    John Lauriello
    Department of Psychiatry, University of New Mexico, Albuquerque, NM 87131 001, USA
    J Clin Psychiatry 69:790-9. 2008
    ..To examine the efficacy and tolerability of a new injectable formulation of olanzapine, olanzapine long-acting injection (LAI), relative to placebo for treatment of acutely ill patients with schizophrenia...
  4. ncbi request reprint Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia
    Juan R Bustillo
    Department of Psychiatry, University of New Mexico, Albuquerque, NM 87131 0001, USA
    Neuropsychopharmacology 33:2456-66. 2008
    ..Early in the illness, schizophrenia patients already demonstrate subtle reductions in NAA. Treatment with typical or atypical antipsychotic medications for several months does not result in NAA changes...
  5. pmc The MCIC collection: a shared repository of multi-modal, multi-site brain image data from a clinical investigation of schizophrenia
    Randy L Gollub
    Department of Psychiatry, Massachusetts General Hospital, Building 120, Suite 101D, Charlestown, MA 02129 2000, USA
    Neuroinformatics 11:367-88. 2013
    ..This manuscript describes the inclusion/exclusion criteria, imaging parameters and other information that will assist those wishing to use this data repository. ..
  6. pmc Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla
    Juan R Bustillo
    Department of Psychiatry, University of New Mexico, Albuquerque, New Mexico, USA
    Biol Psychiatry 69:19-27. 2011
    ..We examined the relationship between glutamate metabolism and cognitive function in schizophrenia...
  7. pmc Dysregulation of working memory and default-mode networks in schizophrenia using independent component analysis, an fBIRN and MCIC study
    Dae Il Kim
    The MIND Research Network, Albuquerque, New Mexico 87131, USA
    Hum Brain Mapp 30:3795-811. 2009
    ....
  8. ncbi request reprint Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure
    Juan R Bustillo
    Department of Psychiatry, Research Division, University of New Mexico, 2400 Tucker NE, Albuquerque, NM 87131, USA
    Schizophr Res 58:313-21. 2002
    ..The well-described reduced frontal NAA in schizophrenia may not be a trait of the illness but may represent medication effect or progression of the disease...
  9. ncbi request reprint Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels
    Juan Bustillo
    Department of Psychiatry, University of New Mexico Health Sciences Center, Albuquerque, NM 87131 0001, USA
    Neuropsychopharmacology 31:751-6. 2006
    ..The documented lower NAA in chronically treated schizophrenia patients is most likely not a simple effect of antipsychotic medications...
  10. ncbi request reprint Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study
    Laura M Rowland
    Department of Psychiatry, MIND Imaging Center, University of New Mexico, USA
    Am J Psychiatry 162:394-6. 2005
    ..The authors' goal was to test in humans the hypothesis that N-methyl-d-aspartate receptor (NMDAR) antagonism results in increased cortical glutamate activity, as proposed by the NMDAR hypofunction model of schizophrenia...
  11. pmc Cigarette smoking and white matter microstructure in schizophrenia
    Kathryn R Cullen
    Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA
    Psychiatry Res 201:152-8. 2012
    ..Further, low FA in specific brain areas may be a neural marker for complex pathophysiology and risk for diverse problems such as schizophrenia, low IQ, and nicotine addiction...
  12. ncbi request reprint Integrated treatment of schizophrenia
    Roshel Lenroot
    Department of Psychiatry, School of Medicine, University of New Mexico, 2400 Tucker NE, Albuquerque, NM 87131, USA
    Psychiatr Serv 54:1499-507. 2003
    ..Emphasis is placed on areas of interaction, including patient adherence and the effect of antipsychotic medications on cognitive functioning. Recommendations are presented for specific clinical situations...
  13. doi request reprint Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychopharmacol 28:S29-35. 2008
    ..4 msec (haloperidol) at end point. Iloperidone demonstrated long-term efficacy equivalent to haloperidol and a favorable long-term safety profile, potentially making this agent a suitable option as maintenance therapy for schizophrenia...
  14. ncbi request reprint Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients
    Juan R Bustillo
    Department of Psychiatry, Research Division, 2400 Tucker NE, University of New Mexico, Albuquerque, NM 87131, USA
    Neuropsychopharmacology 28:527-9. 2003
    ..Serotonin reuptake inhibitors are probably not a practical option to counteract weight gain induced by atypical antipsychotics. Atypical-induced weight gain may result from mechanisms other than 5HT reuptake blockade...
  15. ncbi request reprint Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels
    Juan Bustillo
    Department of Psychiatry, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
    Schizophr Res 66:31-9. 2004
    ..We studied in the rat the effect of antipsychotic drugs on NAA in several brain regions where NAA reductions have been reported in chronically medicated patients with schizophrenia...
  16. ncbi request reprint Reproducibility of 1H-MRS measurements in schizophrenic patients
    Paul G Mullins
    MIND Imaging Center, University of New Mexico, Albuquerque, New Mexico 87131, USA
    Magn Reson Med 50:704-7. 2003
    ..These results extend previous studies of healthy, normal subjects, and establish that it is possible to obtain reliable measures of brain metabolites in clinical populations...
  17. ncbi request reprint Patient and psychiatrist ratings of hypothetical schizophrenia research protocols: assessment of harm potential and factors influencing participation decisions
    Laura Weiss Roberts
    Empirical Ethics Group, University of New Mexico School of Medicine, Albequerque 87156 5326, USA
    Am J Psychiatry 159:573-84. 2002
    ....
  18. doi request reprint Long-acting injectable aripiprazole: how might it fit in our tool box?
    Ganesh Gopalakrishna
    Department of Psychiatry, University of Missouri Columbia, 3 Hospital Drive, Columbia, MO 65212, USA
    Clin Schizophr Relat Psychoses 7:87-92. 2013
    ..All things considered, we welcome our new tool, ALAI, to our work-place and predict both clinical practice and post marketing analysis and studies will discover its true value. ..
  19. pmc Brain-performance correlates of working memory retrieval in schizophrenia: a cognitive modeling approach
    Gregory G Brown
    Department of Psychiatry, University of California, San Diego, CA, USA
    Schizophr Bull 35:32-46. 2009
    ..The results show at both cognitive and neural levels that disordered memory scanning contributes to deficient SIRP performance among schizophrenia patients...
  20. pmc Voxel-based morphometric multisite collaborative study on schizophrenia
    Judith M Segall
    The MIND Research Network, Albuquerque, NM 87131, USA
    Schizophr Bull 35:82-95. 2009
    ....
  21. ncbi request reprint Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial
    H George Nurnberg
    Department of Psychiatry, Health Sciences Center, University of New Mexico School of Medicine, 2400 Tucker NE, Albuquerque, NM 87131 5288, USA
    JAMA 289:56-64. 2003
    ..Sexual dysfunction is a common adverse effect of antidepressants that frequently results in treatment noncompliance...
  22. ncbi request reprint High choline concentrations in the caudate nucleus in antipsychotic-naive patients with schizophrenia
    Juan R Bustillo
    Department of Psychiatry, University of New Mexico School of Medicine, 87131, USA
    Am J Psychiatry 159:130-3. 2002
    ..Proton magnetic resonance spectroscopy ((1)H-MRS) studies of medicated patients with schizophrenia suggest high choline levels in the caudate nucleus. However, assessments of antipsychotic-naive patients are needed...
  23. ncbi request reprint Great(er) expectations
    John Lauriello
    Am J Psychiatry 164:377-9. 2007
  24. ncbi request reprint Selective cognitive impairments associated with NMDA receptor blockade in humans
    Laura M Rowland
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Neuropsychopharmacology 30:633-9. 2005
    ..Impaired cognition is a core feature of schizophrenia. A better understanding of NMDA antagonism, its physiological and cognitive consequences, may provide improved models of psychosis and cognitive therapeutics...

Research Grants3

  1. Relapse Prevention: Long Acting Atypical Antipsychotics
    John Lauriello; Fiscal Year: 2007
    ..Even relatively modest delays in relapse and improvement of long term functioning potentially resulting from a long acting second-generation medication can translate into substantial public health benefits. ..